Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GPR27 | Q9NS67 | 3/20 | 0.41 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | CASP1 | P29466 | 1/20 | 0.40 |
| ▸ | ACLY | P53396 | 1/20 | 0.40 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5536615 | 0.84 | KMT2A (0.47) | POLBLMNASMN1; SMN2MEN1KMT2A | |
| SCHEMBL5537750 | 0.82 | SMN1; SMN2 (0.46) | POLBEGFRLMNASMN1; SMN2MEN1 | |
| SCHEMBL5535242 | 0.82 | SMN1; SMN2 (0.46) | POLBEGFRLMNASMN1; SMN2MEN1 | |
| SCHEMBL29565765 | 0.80 | DAO (0.48) | POLBGRM4EGFRLMNASMN1; SMN2 | |
| SCHEMBL22044890 | 0.78 | LMNA (0.42) | POLBEGFRLMNASMN1; SMN2MEN1 | |
| SCHEMBL21802611 | 0.75 | LIMK2 (0.50) | GRM4SMN1; SMN2MEN1KMT2APGR | |
| SCHEMBL5537363 | 0.74 | L3MBTL1 (0.46) | POLBGRM4EGFRLMNASMN1; SMN2 | |
| SCHEMBL21802604 | 0.71 | MAP2K1 (0.45) | POLBEGFRLMNASMN1; SMN2MEN1 | |
| SCHEMBL12468392 | 0.70 | MEN1 (0.53) | POLBGRM4LMNAMEN1KMT2A | |
| SCHEMBL5537048 | 0.70 | LMNA (0.44) | POLBEGFRLMNASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110869369-B | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2022-06-28 | — | — | CN | disclosed |
| US-11292787-B2 | Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof | XIAMEN UNIVERSITY (CN) | 2022-04-05 | — | — | US | disclosed |
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | Amcure Biosciences Pte. Ltd. (SG) | 2020-06-04 | — | — | US | disclosed |
| CN-110869369-A | Five-membered and six-membered nitrogen heteroaromatic ring compound, preparation method thereof, medicinal composition and application thereof | 厦门大学 | 2020-03-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200172521-A1 | Five-Membered-Fused-Six-Membered Aza-Aromatic Ring Compound, Preparation Method Thereof, Pharmaceutical Composition And Application Thereof | KRAS, NRAS, RASSF5 | POLB 3970/4885GRM4 4376/4885EGFR 641/4885 |
| US-11292787-B2 | Five-membered-fused-six-membered aza-aromatic ring compound, preparation method thereof, pharmaceutical composition and application thereof | KRAS, NRAS, RASSF5 | POLB 3970/4885GRM4 4376/4885EGFR 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.